Trial Profile
Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 31 Jan 2023 Status changed from active, no longer recruiting to completed.
- 14 Mar 2022 Planned End Date changed from 22 Oct 2021 to 30 Dec 2022.
- 15 Dec 2020 Planned End Date changed from 22 Oct 2020 to 22 Oct 2021.